- Home
- RARE vs QTWO Comparison
RARE vs QTWO Comparison
Compare RARE & QTWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- QTWO
- Stock Information
- Founded
- RARE 2010
- QTWO 2004
- Country
- RARE United States
- QTWO United States
- Employees
- RARE N/A
- QTWO N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- QTWO Computer Software: Prepackaged Software
- Sector
- RARE Health Care
- QTWO Technology
- Exchange
- RARE Nasdaq
- QTWO Nasdaq
- Market Cap
- RARE 5.2B
- QTWO 4.8B
- IPO Year
- RARE 2014
- QTWO 2014
- Fundamental
- Price
- RARE $43.98
- QTWO $104.66
- Analyst Decision
- RARE Strong Buy
- QTWO Buy
- Analyst Count
- RARE 14
- QTWO 16
- Target Price
- RARE $88.43
- QTWO $93.44
- AVG Volume (30 Days)
- RARE 717.6K
- QTWO 733.6K
- Earning Date
- RARE 02-13-2025
- QTWO 02-19-2025
- Dividend Yield
- RARE N/A
- QTWO N/A
- EPS Growth
- RARE N/A
- QTWO N/A
- EPS
- RARE N/A
- QTWO N/A
- Revenue
- RARE $522,745,000.00
- QTWO $675,537,000.00
- Revenue This Year
- RARE $27.36
- QTWO $13.23
- Revenue Next Year
- RARE $18.61
- QTWO $11.34
- P/E Ratio
- RARE N/A
- QTWO N/A
- Revenue Growth
- RARE 27.44
- QTWO 10.92
- 52 Week Low
- RARE $37.02
- QTWO $39.66
- 52 Week High
- RARE $60.37
- QTWO $112.82
- Technical
- Relative Strength Index (RSI)
- RARE 33.50
- QTWO 54.58
- Support Level
- RARE $41.45
- QTWO $101.37
- Resistance Level
- RARE $50.00
- QTWO $108.51
- Average True Range (ATR)
- RARE 1.83
- QTWO 3.64
- MACD
- RARE -0.31
- QTWO -1.18
- Stochastic Oscillator
- RARE 26.55
- QTWO 38.55
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About QTWO Q2 Holdings Inc.
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.